Physician profile
Debbie Devine
NPI 1578614590
$4,747.53
in general payments reported to CMS, 2019-2025
24 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 98% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $755 · 2023: $1,257 · 2024: $949 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,858.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $989.29 | 2022-2025 | |
| Genzyme Corporation | $487.73 | 2022-2025 | |
| Abbott Laboratories | $317.16 | 2023-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi Pasteur INC. | $290.31 | 2023-2025 | |
| Corcept Therapeutics | $275.68 | 2024-2025 | Korlym |
| Neurocrine Biosciences, INC. | $253.47 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $220.79 | 2022-2023 | Austedo |
| Boston Scientific Corporation | $219.36 | 2024-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $205.61 | 2024-2025 | |
| Amgen INC. | $151.17 | 2024-2025 | Otezla |
| Actelion Pharmaceuticals US, INC. | $147.73 | 2025 | Uptravi, Opsumit |
| Dexcom, INC. | $130.30 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Cvrx, INC. | $122.01 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $121.24 | 2024 | Airsupra |
| Novo Nordisk INC | $120.74 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
| Paratek Pharmaceuticals, INC. | $113.72 | 2025 | Nuzyra |
| Abiomed | $102.96 | 2023 | Impella |
| Johnson & Johnson Health Care Systems INC. | $93.08 | 2022 | |
| Lilly USA, LLC | $82.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $82.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $62.40 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $27.08 | 2023 | Evkeeza |
| Organon LLC | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.